GRO Biosciences Expands Executive Team with Appointment of Biopharma Veteran Tracey Lodie, PhD as Chief Development Officer
Dr. Lodie most recently worked as Chief Scientific Officer at Quell Therapeutics where she led the company’s scientific strategy and worked to build their immune-driven pipeline.
- Dr. Lodie most recently worked as Chief Scientific Officer at Quell Therapeutics where she led the company’s scientific strategy and worked to build their immune-driven pipeline.
- “We are delighted to add Tracey to our executive team.
- Her world-class experience in immunology, clinical translation, development, and commercialization will be instrumental as we advance our programs into the clinic,” said Daniel J. Mandell, PhD, Chief Executive Officer of GRO Biosciences.
- Dr. Lodie’s addition to the executive team brings critical management expertise to support the continued evolution of GRO Biosciences into a clinical-stage organization.”